Genelux vs Virax Biolabs
GNLX and VRAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GNLX and VRAX compare
Virax Biolabs scores higher on the StockData Score (9 against 5 for Genelux), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GNLX | VRAX |
|---|---|---|
| Size and price | ||
| Market cap | $84.4M | – |
| Share price | $1.86 | $0.613 |
| Change, 1 year | −68.5% | −94.7% |
| Beta (5Y) | 0.61 | 1.61 |
| StockData Score | ||
| Total score | 5 | 9 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 3 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 5.2× | – |
| FCF yield | −34.0% | – |
| Growth | ||
| Revenue growth (TTM) | – | 96.2% |
| Revenue growth, 5Y average | – | −36.9% |
| Profitability | ||
| Gross margin | – | 61.9% |
| Operating margin | – | −51515% |
| Net margin | – | −40439% |
| FCF margin | – | −39264% |
| Return on equity | −178% | −75.7% (better) |
| Return on invested capital | – | −388% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 2.39 | 9.97 (better) |
| Altman Z-score | −15.19 | – |
| Piotroski F-score | 1 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | −22.4% | – |
| Shareholder yield | −22.4% | – |
| Ownership | ||
| Held by institutions | 21.7% | 0.00% |
| Held by insiders | 7.7% | 63.6% |
| Insider net buying, 12 months | −$341K | – |
| Short interest, % of float | 10.9% | 3.2% |
Go deeper
- GNLX stock overview
- GNLX income statement
- GNLX valuation and score
- VRAX stock overview
- VRAX income statement
- VRAX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.